申请人:Eli Lilly and Company
公开号:US07968585B2
公开(公告)日:2011-06-28
The present invention discloses novel compounds of Formula (I): having 11β-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11β-HSD type 1 activity.
本发明披露了一种新型的化合物,其化学式为(I),具有11β-HSD类型1拮抗剂活性,以及制备这种化合物的方法。在另一种实施方式中,本发明披露了包括化合物I的药物组合物,以及使用这些化合物和组合物治疗糖尿病、高血糖、肥胖症、高血压、高脂血症、代谢综合征和其他与11β-HSD类型1活性相关的疾病的方法。